title: Switching biological agents for psoriasis in secondary care: a single-centre, retrospective, open-label study.
authors.affiliation: Royal Free NHS Trust, London, NW3 2QG, U.K.
authors.forename: W A
authors.initials: WA
authors.lastname: Woo
authors.forename: A
authors.initials: A
authors.lastname: Waite
authors.forename: M H A
authors.initials: MH
authors.lastname: Rustin
authors.forename: S R
authors.initials: SR
authors.lastname: McBride
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001685:Biological Factors / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D057915:Drug Substitution; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012189:Retrospective Studies; D063127:Secondary Health Care / Q000379:methods; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001685:Biological Factors; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept